IndyGeneUS AI is a black-owned and service disabled veteran-owned and operated small business (SDVOSB) that is driving precision medicine by leveraging data mining and artificial intelligence to expedite the development and manufacturing of quality targeted therapies, bringing them to market faster.
What is the problem?
IndyGeneUS AI is a genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity. The lack of diversity in clinical trials and drug discovery presents a unique business case for IndyGeneUS to be the leader in driving precision health equity through aggregated genomic and clinical data of the underserved and underrepresented. Large Pharma and CROs would pay premium to obtain rich datasets which represent the demographic of the population they serve. However, they have struggled and failed at miserably at this objective.
What is their solution?
IndyGeneUS AI is an innovative cell and gene therapy company that's focused on contract development and manufacturing organization (CDMO) based in Washington, DC. Our integrated and comprehensive service offerings provides a one-stop solution to get Advanced Therapies to market faster with exceptional quality. IndyGeneUS AI utilizes a client-driven model paired with a patient-centric culture to deliver high-quality and reliable processes, analytical development, viral vector manufacturing, GMP testing, cell therapy bioprocessing, plasmid production, and cell banking services throughout the entirety of a product’s life cycle.
